ClinicalTrials.gg
RecruitingNCT06684106URSTARUpdated Jun 30, 2026

Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance

An interventional study of Ursodeoxycholic acid (UDCA) 500 mg and Placebo in Hyperlipidemia, Ursodeoxycholic Acid and Statin Therapy, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:

  • Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?
  • Will the use of UDCA decrease other adverse events in patients taking oral statins?

Participants will:

  • Take Atorvastatin combined with UDCA or a placebo daily for 6 months
  • Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.
02

Conditions studied

  • Hyperlipidemia
  • Ursodeoxycholic Acid
  • Statin Therapy
  • Glucose Intolerance
03

In context

Hyperlipidemias

861 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

This study's planned enrollment of 128 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 314 studies on the registry; 87 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old.
  • LDL-C≥3.4mmol/l (130 mg/dL).
  • Glycosylated ≤ 6.0% (42 mmol/mol).
  • Voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of diabetes or prediabetes.
  • Past or current use of hypoglycemic drugs.
  • Oral administration of statin lipid-lowering drugs within three months before enrollment.
  • Combined oral drug quantity ≥3.
  • History of ASCVD (previous myocardial infarction, ACS, stroke or within 1 year, symptomatic peripheral vascular disease).
  • Active liver disease (defined as elevation of (ALT), aspartate aminotransferase (AST) >2 × (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.
  • Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.
  • Estimated (eGFR) ≤ 30 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method
  • (NYHA) Class IV heart failure or a known \< 25%
  • A and drug- or ablation-resistant arrhythmia within 3 months prior to randomization
  • An acute or severe systemic infection, or any of the following diseases: hematological disorders, disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status
  • Scheduled for surgery within 6 months
  • Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion
  • Subjects with alcohol or other drug addiction
  • Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome
  • A history of allergic reaction to any study drug or its or similar chemical classes of drugs
  • A family history of homozygous familial hypercholesterolemia
  • Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up
  • Any condition that the investigator considers unsuitable for participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Ursodeoxycholic acid group

    Ursodeoxycholic acid (UDCA) 500 mg: This group of participants receive UDCA 500mg per day.

    Drug: Ursodeoxycholic acid (UDCA) 500 mg

  • Placebo comparator
    placebo group

    This group of participants receive placebo.

    Drug: Placebo

Interventions

  • UDCA together with statin in eligible participants

    Also known as: Ursodeoxycholic Acid, UDCA

  • DrugPlacebo

    placebo together with statin in ASCVD patients

06

What researchers measure

Primary outcomes

  1. HbA1c

    Changes of glycosylated hemoglobin after taking ursodeoxycholic acid for half a year

    Time frame: 6 months after randomization

Secondary outcomes

  1. Concentration of fasting blood glucose

    The concentration of fasting blood glucose was measured and serum was extracted for laboratory testing.

    Time frame: 6 months after randomization

  2. Concentration of fasting islets

    The concentration of fasting islets was measured and serum was extracted for laboratory testing. we use the level of physiological parameter to describe the concentration of fasting islets.

    Time frame: 6 months after randomization

  3. Concentration of blood lipid

    The concentration of blood lipid was measured and serum was extracted for laboratory testing.we use the level of physiological parameter to describe the concentration of blood lipid, including "the level of triglycerides","the level of low-density lipoprotein", "the level of high-density lipoprotein", "the level of total cholesterol" ,"the level of Lipoprotein(a)".

    Time frame: 6 months after randomization

  4. Body composition analysis Fat mass

    The Body composition analysis was measured by the Inbody. we wue the physiological parameter to describe the body composition. e.g."Fat mass"

    Time frame: 6 months after randomization

  5. Body composition analysis Muscle mass

    The Body composition analysis was measured by the Inbody. we wue the physiological parameter to describe the body composition. e.g. "Muscle mass".

    Time frame: 6 months after randomization

07

Study locations

2 of 2 sites recruiting
  • Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
  • The First Affiliated Hospital of Xi 'an Jiaotong University
    Xi'an, China
    Recruiting
08

References and documents

Publications

  • Yu Y, Zheng J, She J, Yuan Z, Wu Y. Effects of ursodeoxycholic acid on statin-induced impaired glucose tolerance: study protocol for a randomized controlled trial. BMJ Open. 2026 Jul 28;16(7):e117417. doi: 10.1136/bmjopen-2026-117417. PubMed 42521308 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to participant privacy and ethical restrictions.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06684106
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Nov 25, 2024
Primary completion
Nov 11, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Yue Yu
Contact
yueyu05@163.com
0086-85323810
Yue Wu, Professor
Contact
imyuewu@qq.com
0086-029-8532-3664
Zuyi Yuan, Professor
study chair · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ursodeoxycholic Acid

Start the discussion